Drugs

Article	Citations
Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease	379
Iruplinalkib: First Approval	302
Empagliflozin: A Review in Symptomatic Chronic Heart Failure	269
Mirvetuximab Soravtansine: First Approval	247
Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review	217
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases	208
Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations	193
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	187
Olutasidenib: First Approval	164
Eye Involvement and Management in Inherited Epidermolysis Bullosa	156
Spesolimab for the Treatment of Generalized Pustular Psoriasis	135
Ensifentrine: First Approval	132
Imetelstat: First Approval	116
Bone Fragility in Diabetes and its Management: A Narrative Review	111
Targeting DNA Damage Response Deficiency in Thoracic Cancers	98
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?	94
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis	92
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors	89
Tarlatamab: First Approval	88
New Topical Therapies in Development for Atopic Dermatitis	85
Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer	85
Difelikefalin: First Approval	85
Epcoritamab: First Approval	81
New Therapeutic Horizons in Chronic Kidney Disease: The Role of SGLT2 Inhibitors in Clinical Practice	78
Amisulpride: A Review in Post-Operative Nausea and Vomiting	78

Authors’ Reply to Bonnet et al. “Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update”	76
A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain?	75
Correction: Vorasidenib: First Approval	71
Vorasidenib: First Approval	71
Comment on: “The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab”	70
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials	70
Arimoclomol: First Approval	69
Xanomeline/Trospium Chloride: First Approval	69
Mobocertinib: First Approval	68
Envafolimab: First Approval	66
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease	66
Innovation in Targeted Intra-articular Therapies for Osteoarthritis	66
Vosoritide: First Approval	65
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using	63
Aprocitentan: First Approval	63
Tunlametinib: First Approval	62
Sulbactam/Durlobactam: First Approval	61
Casirivimab/Imdevimab: First Approval	61
Teclistamab: First Approval	60
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	60
Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets	60
Ocrelizumab: A Review in Multiple Sclerosis	60
Glofitamab: First Approval	60
Potential Therapeutic Agents That Target ATP Binding Cassette A1 (ABCA1) Gene Expression	59
Imeglimin Hydrochloride: First Approval	58
Avalglucosidase alfa: First Approval	57
Pharmacological Treatment for Pedophilic Disorder and Compulsive Sexual Behavior Disorder: A Review	57
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?	57
Givosiran: A Review in Acute Hepatic Porphyria	57
Trofinetide: First Approval	57
New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma	57
Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy	57
Contemporary Management of Dyslipidemia	57
Tebentafusp: First Approval	57
Savolitinib: First Approval	55
20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults	54
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments	54
Etrasimod: First Approval	54
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease	53
Pimitespib: First Approval	53
Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies	53
Coronary Microvascular Dysfunction in Patients with Non-Obstructive Coronary Arteries: Current Gaps and Future Directions	52
Bimekizumab for the Treatment of Psoriasis	50
Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain	50
Gastrointestinal Dysfunction in Parkinson’s Disease	50
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations	47
Bexagliflozin: First Approval	47
Tremelimumab: First Approval	47
Current Medical Therapy for Adenomyosis: From Bench to Bedside	46
New Therapies on the Horizon for Primary Biliary Cholangitis	46

Beremagene Geperpavec: First Approval	46
Dimdazenil: First Approval	46
Tirzepatide: First Approval	46
Vamorolone: First Approval	45
Sotorasib: First Approval	44
Inclisiran: First Approval	44
Correction: Iptacopan: First Approval	43
Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval	43
Correction to: Interchangeability of Biosimilars: Overcoming the Final Hurdles	43
Correction to: Benefits and Harms of ‘Smart Drugs’ (Nootropics) in Healthy Individuals	43
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression	42
Correction to: Valemetostat Tosilate: First Approval	42
Lotilaner Ophthalmic Solution 0.25%: First Approval	41
Correction to: Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting	41
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1	41
Correction to: Birch Bark Extract: A Review in Epidermolysis Bullosa	41
Correction to: Fostamatinib: A Review in Chronic Immune Thrombocytopenia	40
Correction: Vonoprazan: A Review in Helicobacter pylori Infection	40
Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of Action	40
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections	40
Orexin Receptor Antagonists for the Prevention and Treatment of Alzheimer’s Disease and Associated Sleep Disorders	40
Iptacopan: First Approval	39
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder	39
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile I	39
Capivasertib: First Approval	39
Zavegepant: First Approval	39
The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis	39
Correction to: Secukinumab: A Review in Psoriatic Arthritis	38
Zastaprazan: First Approval	38
Motixafortide: First Approval	38
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments	37
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema	37
Eftrenonacog Alfa: A Review in Haemophilia B	37
Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain	37
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations	36
Personalized Multimorbidity Management for Patients with Type 2 Diabetes Using Reinforcement Learning of Electronic Health Records	36
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”	36
Correction to: Darinaparsin: First Approval	36
Teprotumumab: A Review in Thyroid Eye Disease	36
Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature	35
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update	35
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin	34
Crovalimab: First Approval	34
Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria	34
The Effect of Biological Treatment on Fatigue in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis	34
Chinese Herbal Medicines for Coronary Heart Disease: Clinical Evidence, Pharmacological Mechanisms, and the Interaction with Gut Microbiota	33
Statins and Gliomas: A Systematic Review of the Preclinical Studies and Meta-Analysis of the Clinical Literature	33
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences	33
Nemolizumab: First Approval	32
Upacicalcet: First Approval	32
Authors’ Reply to Colak et al.: “Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing”	32
Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”	32
Comment on: “Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry”	32
Somatrogon: First Approval	31
Eladocagene Exuparvovec: First Approval	31
Acknowledgement to Referees	30
Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity	30
Repotrectinib: First Approval	30
Dasiglucagon: First Approval	30
Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis	30
Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs	30
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	29
Donafenib: First Approval	29
Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials	29
Androgenetic Alopecia: Therapy Update	29
Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma	29
Tafolecimab: First Approval	29
Diagnosis and Treatment of AL Amyloidosis	28
Sex-Based Outcomes of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis	28
Authors’ Reply to Denning: Comment on: “Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries”	28
Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study	27
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes	26
Finerenone: First Approval	26
Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence?	26
Maribavir: First Approval	26
Clinical Outcomes with GLP-1 Receptor Agonists in Patients with Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials	25
A Multicentric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin®) as a Resuscitative Agent in Hypovolemic Shock Patients	25
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies	25
Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis	25
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure	24

Nogapendekin alfa Inbakicept: First Approval	24
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews	24
On the Verge of Precision Medicine in Diabetes	24
Neuropathic Pain and Spinal Cord Injury: Management, Phenotypes, and Biomarkers	24
Surufatinib: First Approval	24
Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians	23
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry	23
Olipudase Alfa: First Approval	23
Mavorixafor: First Approval	23
Ivonescimab: First Approval	23
Intravenous Methadone for Perioperative and Chronic Cancer Pain: A Review of the Literature	23
Prevention of Rheumatoid Arthritis in At-Risk Individuals: Current Status and Future Prospects	23
RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future	23
Cefepime/Enmetazobactam: First Approval	23
Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics	23